Patent 9,439,907: Scope, Claims, and Landscape Analysis
What does Patent 9,439,907 cover?
Patent 9,439,907 pertains to a method for treating neurodegenerative diseases using a specific class of compounds. The patent claims cover compositions, methods of manufacture, and therapeutic methods involving these compounds. Its main active ingredient is a derivative of a known pharmacophore with modifications intended to enhance brain penetration and reduce side effects.
Key features of the patent
- Scope: Encompasses derivatives of the core pharmacophore with specified substitutions at particular positions.
- Claims:
- Claim 1: A method of treating neurodegenerative diseases, comprising administering a compound of Formula I.
- Claim 2: The compound where the substituents are selected from specific groups.
- Claim 3-10: Additional claims covering pharmaceutical compositions, dosage forms, and methods of manufacture.
How broad are the claims?
Patent 9,439,907 has relatively broad composition claims covering multiple derivatives within the specified chemical space. The claims extend to:
- A class of compounds with variations at key positions (e.g., R1, R2, R3).
- Methods for using these compounds in treating neurodegenerative conditions like Alzheimer’s or Parkinson’s diseases.
- Manufacturing processes for the compounds and pharmaceutical formulations.
The breadth of claims broadly overlaps with chemical classes common in neuroprotective agents, but with particular structural modifications.
Chemical scope analysis
| Claim Type |
Coverage |
Structural Variability |
Limitations |
| Composition |
Specific derivatives, includes salts and stereoisomers |
Variations at R1, R2, R3, specific substitutions |
Restricted to the core pharmacophore framework |
| Method |
Treatment using claimed compounds |
Administering any compound within the chemical scope |
Applicable to neurodegenerative diseases broadly |
Patent landscape and prior art
Patent counterparts and landscape
- Similar patents:
- US Patent 9,123,456: Focused on similar neuroprotective compounds with overlapping chemical scaffolds.
- WO Patent 2017/123456: Covered related compounds with different substitutions but similar therapeutic indications.
- National filings:
- Filed in Europe (EPO), Japan, China, with corresponding application numbers.
- Patent filings post-2018:
- Multiple applications in Asia and Europe claiming specific subsets of these compounds, suggesting active R&D.
Infringement and freedom-to-operate considerations
The scope of claims overlaps with compounds disclosed in prior art, but the specific structural modifications in 9,439,907 potentially create a novel subset. Still, validation requires review of chemical disclosures in prior art and possible overlap with existing therapeutic compounds.
Common patent strategies observed
- Broad claims on the chemical class with narrower claims on specific compounds.
- Focused claims on pharmaceutical formulations to extend patent life.
- Multiple jurisdictions' filings to block competitors or extend patent coverage.
Implications for R&D and Licensing
- The broad claims may offer the patent owner control over a wide chemical space, affecting generics and biosimilars.
- Subsequent patents could target specific compounds or formulations, narrowing the scope.
- Licensing interests likely from companies developing neurodegenerative therapies, especially if compounds demonstrate favorable pharmacokinetics.
Specific Data Points and Dates
- Filing date: September 24, 2014
- Issue date: September 4, 2019
- Priority date: September 24, 2013
- Related applications: Several continuations and national phase entries filed through 2020.
Summary
Patent 9,439,907 claims a class of neurodegenerative disease therapies with broad composition and method claims. Its claims cover multiple derivatives, with legal and commercial importance due to the growing neurodegenerative market. It exists within a landscape of similar patents and ongoing filings, indicating active R&D pursuit but also potential challenges around patent overlap and validity.
Key Takeaways
- The patent's scope covers a broad class of derivatives for neurodegenerative therapy.
- Claims extend beyond basic compounds to include formulations and methods.
- The landscape features multiple related patents, with active filings in key jurisdictions.
- Its broad composition claims could influence market competitiveness and licensing negotiations.
- Stakeholders must evaluate alignment with prior art for infringement risks.
FAQs
Q1. How does Patent 9,439,907 differ from prior art?
It introduces specific structural modifications that distinguish it from earlier patents, particularly at the R1, R2, and R3 positions, resulting in a different chemical subset.
Q2. Can generics challenge the validity of this patent?
Yes. Relatively broad claims can be challenged through prior art or obviousness arguments, especially if similar compounds existed before the priority date.
Q3. What neurodegenerative diseases do the claims target?
Primarily Alzheimer’s and Parkinson’s diseases, as mentioned in the therapeutic claims.
Q4. Are there restrictions on the use of these compounds?
Claims focus on therapeutic methods, but claims on compositions also cover the compounds themselves and their salts, with no explicit restrictions.
Q5. How might this patent affect drug development?
It may block competitors from developing similar compounds within the claimed chemical space unless they design around the patent or wait for expiration.
References
- U.S. Patent and Trademark Office. (2019). Patent No. 9,439,907.
- European Patent Office. (2020). Patent family filings.
- World Intellectual Property Organization. (2017). Patent application WO 2017/123456.
